Clinical Trial Update: ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study [Phase 4]

View source ↗

Summary

This update notes the completion of a Phase 4 trial evaluating the optimal duration of dual antiplatelet therapy in patients with coronary artery disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Snippet

Sponsor: Kyoto University, Graduate School of Medicine | Conditions: Coronary Artery Disease | Phase 4 | Status: COMPLETED